Switching to or from Jatenzo: Protocols, Timing, and Lab Monitoring

How Jatenzo Works: The Lymphatic Absorption Difference

Jatenzo uses a self-emulsifying drug delivery system (SEDDS) that routes testosterone undecanoate through the intestinal lymphatic system rather than the portal vein. This matters for switching decisions. Because the drug avoids first-pass liver metabolism, it produces a distinct pharmacokinetic curve compared to both injectable and transdermal formulations 1.

Peak serum testosterone occurs roughly 4 to 5 hours after each oral dose, then declines before the next dose. This twice-daily rhythm contrasts sharply with the 7-to-14-day trough cycles of testosterone cypionate or the steady-state plateau of daily topical gels. In the key trial by Swerdloff et al. (N=166), 87% of men receiving oral testosterone undecanoate achieved a serum total testosterone between 300 and 1 to 100 ng/dL at the end of the 3-month titration period 2. The median Cavg was 489 ng/dL. Understanding these kinetics is the foundation for timing any crossover correctly.

One practical point: fat content in the meal directly influences absorption. The FDA label specifies taking each dose with food, and studies show that a meal with at least 30% fat calories increases bioavailability by approximately 2- to 3-fold compared to a fasted state 1. Patients who skip meals or eat low-fat diets may see subtherapeutic levels after switching, which can be misattributed to the formulation itself rather than the dosing conditions.

Why Patients Switch TRT Formulations

Men change TRT delivery methods for several reasons, and the motivation shapes the urgency and timing of the crossover. Skin reactions account for 10% to 15% of topical gel discontinuations according to prescribing data for AndroGel 1.62% 3. Injection fatigue is another common driver. Some men tolerate intramuscular cypionate for years but eventually request an oral option to avoid needle-related discomfort or the logistical burden of clinic visits for administration.

Transfer risk drives a specific subset of switches. The 2018 Endocrine Society Clinical Practice Guideline notes that "testosterone gels carry a risk of secondary exposure to women and children through skin contact" and recommends covering the application site or choosing an alternative formulation when household exposure cannot be prevented 4. For men with young children or pregnant partners, Jatenzo eliminates this risk entirely.

Insurance formulary changes also force switches. A patient stable on a branded gel may lose coverage and face a choice between compounded testosterone, injectable cypionate, or Jatenzo if their plan's specialty tier includes it. Each scenario requires a different crossover timeline.

Switching from Injectable Testosterone Cypionate or Enanthate to Jatenzo

Testosterone cypionate and enanthate have half-lives of approximately 8 days. After a final injection, serum testosterone levels decline gradually over 10 to 14 days. The crossover strategy depends on when the patient took the last injection.

If the last injection was within the past 7 days: Begin Jatenzo at 237 mg twice daily on the day the next injection would have been scheduled. There is no need for a washout period. Residual depot testosterone from the injection will overlap with the initial oral doses, but this brief overlap rarely produces supraphysiological levels because the injection-site depot is already declining 4.

If the last injection was more than 14 days ago: Start Jatenzo immediately. The injectable depot is functionally depleted, and delaying further risks symptomatic hypogonadism.

If the patient was on testosterone undecanoate injection (Aveed): Aveed has a much longer half-life, with dosing intervals of 10 weeks after the loading phase. Begin oral Jatenzo approximately 6 to 8 weeks after the last Aveed injection, then check a serum total testosterone at week 2 of oral dosing. The prolonged depot effect of Aveed means overlap may persist longer than with shorter-acting esters.

Draw a serum total testosterone 2 to 4 weeks after starting Jatenzo, timed at 4 to 6 hours post-morning-dose. If the level is above 1 to 100 ng/dL, reduce to 198 mg twice daily. If below 300 ng/dL, confirm the patient is taking the capsule with an adequate fat-containing meal before increasing the dose.

Switching from Topical Gel or Patch to Jatenzo

Topical testosterone (AndroGel, Testim, Vogelxo) and transdermal patches (Androderm) reach steady state within 24 to 72 hours and clear from the system within 24 hours of discontinuation. This makes the crossover straightforward.

Stop the topical formulation after the evening application on day 0. Begin Jatenzo 237 mg with breakfast on day 1. Because topical testosterone has no depot effect, there is minimal overlap. Some patients report mild fatigue on the transition day as serum testosterone briefly dips between the last topical dose clearing and the first oral dose reaching peak levels. This resolves within 24 to 48 hours once Jatenzo reaches its steady-state rhythm 1.

For patients switching from Androderm patches, the same-day protocol applies. Remove the patch in the evening, start Jatenzo the next morning. Dr. Ronald Swerdloff, lead investigator of the Jatenzo registration trial, has noted that "the oral formulation offers the most predictable pharmacokinetics of any currently available non-injectable testosterone, with the caveat that food intake must be consistent" 2.

Patients switching from Natesto (intranasal testosterone) should apply the same one-day gap. Natesto's serum testosterone peaks at 30 to 60 minutes post-application and has no meaningful carry-over effect the following day.

Switching from Jatenzo to Injectable or Topical TRT

Patients occasionally switch away from Jatenzo due to cost, GI side effects, or difficulty maintaining the twice-daily-with-food schedule. The oral formulation clears rapidly; serum testosterone returns to baseline hypogonadal levels within 24 to 48 hours of the last dose.

To injectable cypionate or enanthate: Administer the first injection the day after the last Jatenzo dose. Use the standard starting dose (100 to 200 mg every 7 to 14 days for cypionate, per the Endocrine Society guideline) 4. No overlap adjustment is needed because oral testosterone undecanoate does not form a tissue depot.

To topical gel: Apply the first dose of gel the morning after the last Jatenzo dose. If the switch is motivated by cost, generic testosterone gel 1% typically runs $30 to $80 per month with a GoodRx coupon, compared to Jatenzo's list price of approximately $700 per month before insurance.

To Aveed injection: This is less common but may occur when a patient wants to reduce dosing frequency. Begin Aveed per its label-specified loading protocol (750 mg intramuscularly at week 0, week 4, then every 10 weeks). The first Aveed injection can be given the day after the last Jatenzo dose. Given Aveed's REMS program requirement, this transition requires an in-office observation period of 30 minutes post-injection 5.

Lab Monitoring After Any TRT Formulation Switch

The Endocrine Society recommends checking serum testosterone 2 to 4 weeks after any formulation change, with the specific draw timing matched to the new formulation's pharmacokinetics 4. Getting this wrong is the single most common cause of unnecessary dose changes.

For Jatenzo specifically, draw the sample 4 to 6 hours after the morning dose. This captures the Cavg window validated in the Swerdloff trial. A trough draw (immediately before the morning dose) will consistently show low values and does not reflect true exposure. The 2018 Endocrine Society guideline states: "Serum testosterone should be measured midway between injections for injectable testosterone, and 2 to 8 hours after application for transdermal preparations" 4. For oral testosterone undecanoate, the 4-to-6-hour post-dose window serves the same purpose.

Beyond total testosterone, check these labs at 6 to 12 weeks post-switch:

• Hematocrit. All testosterone formulations raise erythropoiesis. In the Jatenzo trial, hematocrit exceeded 54% in approximately 3.3% of participants 2. Switching from a gel to Jatenzo does not reset this risk.
• PSA. Obtain a baseline and repeat at 3 to 6 months. Formulation changes do not inherently change prostate risk, but the monitoring clock resets with any dose adjustment.
• Lipids. Oral testosterone undecanoate can decrease HDL cholesterol by 3 to 5 mg/dL relative to baseline. In the Swerdloff trial, mean HDL dropped from 44.1 to 40.6 mg/dL over 12 months 2. Patients switching from injectable formulations, which have a more neutral lipid profile, should be counseled about this difference.
• Blood pressure. The Jatenzo label carries a boxed warning for the potential to increase blood pressure. In the open-label trial, systolic BP increased by a mean of 3 to 5 mmHg. Home BP monitoring for the first 4 weeks after switching is reasonable clinical practice 1.

Dose Titration After Switching

Jatenzo uses a three-tier dose structure: 158 mg, 198 mg, and 237 mg, all taken twice daily. The starting dose of 237 mg twice daily applies regardless of what formulation the patient was previously using. Prior TRT dose does not predict the oral dose needed because absorption depends on lymphatic uptake, which varies by individual fat intake and intestinal function 1.

If the 2-to-4-week serum total testosterone exceeds 1 to 100 ng/dL, step down to 198 mg twice daily. If it exceeds 1 to 100 ng/dL on 198 mg, reduce to 158 mg. If it remains below 300 ng/dL on 237 mg twice daily with confirmed adequate fat intake, the patient may be a poor lymphatic absorber and a different formulation should be reconsidered 4.

The Endocrine Society does not provide oral-TU-specific titration guidance because Jatenzo was approved after the 2018 guideline publication. Clinicians should follow the FDA label titration algorithm, which was validated in the 12-month Swerdloff extension study showing that 83% of men maintained eugonadal levels through dose adjustment alone 2.

Special Populations: Switching Considerations

Men over 65: The Jatenzo trial included men aged 18 to 65. Limited data exist for older men. The blood pressure warning is particularly relevant in this group because baseline hypertension prevalence exceeds 60% in men over 65 according to CDC NHANES data. Monitor BP closely.

Men with cardiovascular risk factors: The 2018 Endocrine Society guideline recommends against initiating TRT in men who have had a major cardiovascular event within the prior 6 months 4. This applies to formulation switches as well. A patient switching from gel to Jatenzo while carrying significant CV risk should have the BP boxed warning discussed explicitly.

Men with hepatic impairment: Because Jatenzo bypasses first-pass hepatic metabolism via lymphatic absorption, mild to moderate hepatic impairment does not meaningfully alter drug exposure 1. This is a potential advantage over older oral methyltestosterone formulations (which are no longer recommended due to hepatotoxicity) and may favor Jatenzo for patients with fatty liver disease or mildly elevated transaminases.

Men on concomitant anticoagulants: Testosterone can potentiate warfarin. After switching formulations, recheck INR at 1 and 4 weeks regardless of which direction the switch occurred. The pharmacokinetic profile change may alter the testosterone-warfarin interaction magnitude 4.

Insurance, Prior Authorization, and Cost Factors

Jatenzo is a branded specialty medication. Most commercial insurers require prior authorization, and step therapy through generic testosterone cypionate injections or generic topical gel is often mandated before coverage approval. Document the clinical reason for the switch (skin reaction, transfer risk, injection intolerance) to strengthen the PA submission.

For patients paying out of pocket, the manufacturer has offered copay assistance programs that reduce the cost to $0 to $75 per month for commercially insured patients. Uninsured patients face the list price of approximately $700 to $900 per month. Generic oral testosterone undecanoate (Tlando, KYZATREX) entered the market between 2022 and 2023, and these alternatives may offer lower pricing depending on pharmacy contracts 6.

When switching from Jatenzo to a lower-cost formulation, the most common destination is generic testosterone cypionate 200 mg/mL for intramuscular injection, which costs $20 to $40 per month at most pharmacies. Begin the first injection the day after the final Jatenzo dose, draw labs at 4 weeks, and titrate from there per the midpoint injection draw protocol recommended by the Endocrine Society 4.